Treatment satisfaction in people with type 2 diabetes mellitus treated with once-weekly dulaglutide: data from the AWARD-1 and AWARD-3 clinical trials
A randomized, placebo-controlled trial involving patients with metabolic syndrome found that supplementing with just 300 mg/day of ALA for four weeks improved flow-mediated vasodilation (FMD) by a staggering 44%
In a world with one drug, the matching problem is invisible
Its broad receptor interaction profile has made it a valuable tool for investigating melanocortin receptor pharmacology, ligand-receptor binding dynamics, receptor activation mechanisms, and subtype-specific signaling pathways
PlexusDx patients considering breastfeeding should discuss these molecular realities with their prescriber, as this evidence helps contextualize risk differently than outdated assumptions about all medications
More serious risks discussed in class labeling include pancreatitis and gallbladder problems, and the approved products carry contraindications related to a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
